BioAffinity Technologies (NASDAQ:BIAFW) Stock Price Down 7.6%
BioAffinity Technologies (NASDAQ:BIAFW) Stock Price Down 7.6%
bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Rating) shares fell 7.6% on Tuesday . The stock traded as low as $0.35 and last traded at $0.49. 9,877 shares changed hands during trading, a decline of 70% from the average session volume of 33,233 shares. The stock had previously closed at $0.53.
生物親和科技股份有限公司 (NASDAQ: BIAFW — 獲得評級) 股份下跌 7.6% 在星期二.該股價低至 0.35 美元，最後成交價為 0.49 美元。9,877 股在交易過程中轉手，較 33,233 股的平均交易量下降了 70%。該股票之前已收盤 0.53 美元。
bioAffinity Technologies Trading Down 7.6 %
生物親和技術交易下跌 7.6%
The firm has a 50-day simple moving average of $0.43.
該公司的 50 天簡單移動平均線為 0.43 美元。
Institutional Investors Weigh In On bioAffinity Technologies
機構投資者權衡生物親和技術
An institutional investor recently bought a new position in bioAffinity Technologies stock. Armistice Capital LLC acquired a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Rating) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 204,082 shares of the company's stock, valued at approximately $72,000.
一名機構投資者最近購買了生物親和科技股票的新倉位。根據其最近與證券交易委員會的披露，停戰資本有限責任公司在第三季度收購了生物聯合技術公司（NASDAQ：BIAFW-獲得評級）的新股份。該公司收購了該公司股票的 204,082 股，價值約為 72,000 美元。
About bioAffinity Technologies
關於生物親和技術
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level.
BioAffinity 科技有限公司是一家生物技術公司，致力於開發非侵入性診斷測試和靶向癌症治療。該公司提供 CypAth 肺部診斷 test，用於及早發現肺癌。它還研究標靶療法以治療細胞水平的癌症。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on bioAffinity Technologies (BIAFW)
- Will Nordstrom Stock be the Grinch This Year?
- Harpoon Therapeutics Remains Volatile After Promising News
- We Are the Champions: 3 Dividend Growers Wall Street Loves
- What is Market Structure in Trading?
- Institutional Selling Is No Headwind For Nike
- 獲取有關生物親和技術（BIAFW）的免費研究報告
- 諾德斯特龍股票今年會成為聖誕嗎？
- 魚叉治療在有希望的消息後仍然不穩定
- 我們是冠軍：3 股息種植者華爾街愛
- 什麼是交易中的市場結構？
- 機構銷售對耐克來說沒有逆風
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收生物親和技術的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 BioAffinity 技術和相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。